KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom/Impact Scale (GODDESS©): psychometric properties and clinically meaningful thresholds as assessed in the Phase 3 DeFi randomized controlled clinical trial.

Mrinal M Gounder, Thomas M Atkinson, Timothy Bell, Christina Daskalopoulou, Pip Griffiths, Moriah Martindale, L Mary Smith, Allison Lim

Qual Life Res 32(10) 2861-2873

PMID37347393
PMCIDPMC10474203
DOI10.1007/s11136-023-03445-7
发表日期2023-06-22
入排依据:The record describes a secondary analysis evaluating the psychometric properties of a patient-reported outcome tool (GODDESS©) from the Phase 3 DeFi trial. While it is an oncology, human, randomized, Phase 3 trial with a drug intervention and reports original results, it does not present the primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) required for this cohort. The deterministic review correctly identified 'no_time_to_event_signal'.
摘要

摘要

PURPOSE: The GODDESS© tool was developed to assess Desmoid Tumor/Aggressive Fibromatosis (DT/AF) symptom severity and impact on patients' lives. This study evaluated GODDESS©'s cross-sectional and longitudinal measurement properties. METHODS: The Phase 3, randomized placebo-controlled, DeFi study (NCT03785964) of nirogacestat in DT/AF was used to assess GODDESS©'s reliability, construct validity, responsiveness, and estimate of meaningful change thresholds (MCTs). Other patient-reported outcome (PRO) measures included Patient Global Impression of Severity (PGIS) in DT/AF symptoms, EORTC QLQ-C30, Brief Pain Inventory Short Form, and PROMIS Physical Function short-form 10a v2.0 plus 3 items. RESULTS: DeFi participants (N = 142) had a median age of 34 years (range: 18-76) and were mostly female (64.8%), with extra-abdominal (76.8%) or intra-abdominal tumors (23.2%). The GODDESS© symptom/impact scales showed internal consistency at baseline, cycles 4 and 7 (Cronbach's α > 0.70) and test-retest reliability (intra-class correlation coefficient > 0.85). GODDESS© scales correlated moderately to highly with PRO measures capturing similar content and differentiated among PGIS and Eastern Cooperative Oncology Group groups. GODDESS© scales detected improvement over time. For the total symptom score, a 1.30-point decrease was estimated as the within-person MCT and a 1.00-point decrease as the between-group MCT. For the physical functioning impact score, estimated within- and between-group MCTs were 0.60-point and 0.50-point decreases, respectively. Few participants exhibited symptom worsening. CONCLUSION: GODDESS© was found to be reliable, valid, responsive, and interpretable as a clinical trial endpoint in the pooled sample of DT/AF patients. Estimated MCTs can be used to define responders and assess group-level differences in future, unblinded, efficacy analyses. TRIAL REGISTRATION NUMBER AND REGISTRATION DATE: NCT03785964; December 24, 2018.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。